Lidocaine HCl - Hydrocortisone Acetate with Aloe
RxNorm 1012221· LIDOCAINE HCL AND HYDROCORTISONE ACETATE· RECTAL
PureTek Corporation
Indications and usage
INDICATIONS: Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area.
Dosage and administration
DOSAGE AND ADMINISTRATION: Apply product to the affected area(s) twice daily or as directed by a physician. Product should not be used in excess of recommendations or for prolonged use in the anal canal. If the condition does not respond to repeated courses of product or should worsen, discontinue use and seek the advice of your physician. Products without Applicators: Remove the child-resistant cap and foil seal from the tube. Apply a thin film to the affected area. Replace the cap after use. Products with Single-Use Tubes and Applicators: Tear open one cleansing wipe packet (if the product kit contains such item), gently clean the affected area and discard the used cleansing wipe. Remove the child-resistant cap and foil seal from one tube and firmly screw one applicator onto the tube. Do not over tighten. Squeeze the tube to fill the applicator until a small amount of cream/gel comes out of and lubricates the applicator openings. Gently insert the applicator tip with attached tube into anal area. Continue squeezing the body of the tube as it is moved around the areas of discomfort, and lastly, around and in the anal opening (if directed by physician). Do not completely insert the applicator and tube into the anus or insert deep into the rectum. Do not insert a loose applicator tip into the anus or rectum. Once application is completed, both the tube and applicator should be gently removed and discarded. PharmaPure Rx Lidocaine HCl 2.8% - Hydrocortisone Acetate 0.55% Gel with Aloe: Remove the cap and foil seal from the tube and attach one applicator onto the tube. Do not over tighten. Squeeze the tube to fill the applicator until the plunger stops. While maintaining neutral pressure on the tube, separate the applicator from the tube. Replace the cap, roll the tube up from the bottom and save for future use. Gently insert the tip of the filled applicator approximately ½ inch into the anal area and apply steady, even pressure on the plunger, applying 5 mL of gel to the anus and peri-anal area. Do not insert the applicator any additional length into the anus. Once application is completed, remove the applicator and discard. After the final use, also discard the tube. If directed by a physician, a small amount of gel may be applied to the anal area using a fingertip.
Warnings
PRECAUTIONS: For external use only. Not for ophthalmic use. Product and used applicators could harm small children if chewed or swallowed. Keep out of reach of children. Topical formulations of lidocaine may be absorbed to a greater extent through mucous membranes and abraded, fissured or irritated skin than through intact skin. Product should not be ingested or applied into the mouth, inside of the nose or in the eyes. Product should not be used in the ears. Any situation where lidocaine penetrates beyond the tympanic membrane into the middle ear is contraindicted because of ototoxicty associated with lidocaine observed in animals when instilled in the middle ear. Product should not come into contact with the eye or be applied into the eye because of the risk of severe eye irritation and the loss of eye surface sensation, which reduces protective reflexes and can lead to corneal irritation and possibly abrasion. If eye contact occurs, rinse out the eye immediately with saline or water and protect the eye surface until sensation is restored.
Contraindications
CONTRAINDICATIONS: Product should not be used in patients with a history of sensitivity to any of its ingredients or adverse reactions to lidocaine or amide anesthetics, which usually do not cross-react with “caine” ester type anesthetics. If excessive irritation and significant worsening occur, discontinue use and seek the advice of your physician. Product and topical lidocaine should be used cautiously in those with impaired liver function, as well as the very ill or very elderly and those with significant liver disease. Product should be used with caution in patients receiving antiarrhythmic drugs of Class I since the adverse effects are additive and generally synergistic. Product is contraindicated for tuberculous or fungal lesions or skin vaccinia, varicella and acute herpes simplex. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Pregnancy
USE IN PREGNANCY: Teratogenic Effects: Pregnancy Category C Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts or for prolonged periods of time.
Nursing mothers
NURSING MOTHERS: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this drug is administered to a nursing mother.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- anaemia1
- gastrointestinal haemorrhage1
- lower gastrointestinal haemorrhage1
Adverse reactions (label)
ADVERSE REACTIONS: During or immediately following application of product, there may be transient stinging or burning from open areas of skin, or transient blanching (lightening), or erythema (redness) of the skin.
KR · 한국Products in Korea (487)
- 케이리도카인크림9.6%(리도카인)(주)넥스팜코리아
- 케이리도카인크림9.6%(리도카인)(주)넥스팜코리아
- 에카인크림(리도카인)(주)다산제약
- 에카인크림(리도카인)(주)다산제약
- 에카인크림(리도카인)(주)다산제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 리카르로크림(주)동구바이오제약
- 애니맨겔(리도카인)(주)동구바이오제약
- 애니맨겔(리도카인)(주)동구바이오제약
- 애니맨겔(리도카인)(주)동구바이오제약
- 메조인주(염산리도카인)(주)드림파마
- 메조인주(염산리도카인)(주)드림파마
- 엘엠엑스4크림(리도카인)(주)리젠팜
- 엘엠엑스4크림(리도카인4%)(주)리젠팜
View more: Full FDA label on DailyMed →Label effective 20250109